Comparison of clinical features of cystic fibrosis patients eligible but not on CFTR modulators to ineligible for CFTR modulators
dc.contributor.author | Büyüksahin, HN | |
dc.contributor.author | Emiralioglu, N | |
dc.contributor.author | Yalçin, E | |
dc.contributor.author | Sen, V | |
dc.contributor.author | Sen, HS | |
dc.contributor.author | Arslan, H | |
dc.contributor.author | Baskan, AK | |
dc.contributor.author | Çakir, FB | |
dc.contributor.author | Koray, CF | |
dc.contributor.author | Yilmaz, AI | |
dc.contributor.author | Ercan, F | |
dc.contributor.author | Altintas, DU | |
dc.contributor.author | Serbes, M | |
dc.contributor.author | Keskin, Ö | |
dc.contributor.author | Arik, E | |
dc.contributor.author | Gülen, F | |
dc.contributor.author | Barlik, M | |
dc.contributor.author | Karcioglu, O | |
dc.contributor.author | Damadoglu, E | |
dc.contributor.author | Köse, M | |
dc.contributor.author | Ersoy, A | |
dc.contributor.author | Bingöl, A | |
dc.contributor.author | Basaran, E | |
dc.contributor.author | Çakir, EP | |
dc.contributor.author | Aslan, AT | |
dc.contributor.author | Canitez, Y | |
dc.contributor.author | Korkmaz, M | |
dc.contributor.author | Özdemir, A | |
dc.contributor.author | Harmanci, K | |
dc.contributor.author | Soydas, SS | |
dc.contributor.author | Hangül, M | |
dc.contributor.author | Yüksel, H | |
dc.contributor.author | Özcan, G | |
dc.contributor.author | Korkmaz, P | |
dc.contributor.author | Kiliç, M | |
dc.contributor.author | Aydin, ZGG | |
dc.contributor.author | Çaltepe, G | |
dc.contributor.author | Can, D | |
dc.contributor.author | Dogru, S | |
dc.contributor.author | Öztürk, GK | |
dc.contributor.author | Süleyman, A | |
dc.contributor.author | Topal, E | |
dc.contributor.author | Özsezen, B | |
dc.contributor.author | Hizal, M | |
dc.contributor.author | Demirdögen, E | |
dc.contributor.author | Ogun, H | |
dc.contributor.author | Börekçi, S | |
dc.contributor.author | Yazan, H | |
dc.contributor.author | Çakir, E | |
dc.contributor.author | Eyüboglu, TS | |
dc.contributor.author | Çobanoglu, N | |
dc.contributor.author | Cinel, G | |
dc.contributor.author | Pekcan, S | |
dc.contributor.author | Özçelik, U | |
dc.contributor.author | Dogru, D | |
dc.date.accessioned | 2025-04-10T10:37:47Z | |
dc.date.available | 2025-04-10T10:37:47Z | |
dc.description.abstract | Introduction: Cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs target the underlying defect and improve CFTR function. They are a part of standard care in many countries, but not all patients are eligible for these drugs due to age and genotype. Here, we aimed to determine the characteristics of non-eligible patients for CFTR modulators in the CF registry of Turkey (CFRT) to highlight their clinical needs. Methods: This retrospective cohort study included CF patient data from the CFRT in 2021. The decision of eligibility for the CFTR modulator was determined according to the 'Vertex treatment-Finder' on the Vertex (R) website. Demographic and clinical characteristics of patients were compared between eligible (group 1) and ineligible (group 2) groups for CFTR modulators. Results: Among the study population (N = 1527), 873 (57.2%) were in group 1 and 654 (42.8%) were in group 2. There was no statistical difference between groups regarding sex, meconium ileus history, diagnoses via newborn screening, FEV1 z-score, CF-associated complications, organ transplant history, and death. Patients in group 2 had a higher incidence of pancreatic insufficiency (87.7% vs. 83.2%, p = .010), lower median height z-scores (-0.87 vs. -0.55, p < .001), lower median body mass index z-scores (-0.65 vs. -0.50, p < .001), longer days receiving antibiotics due to pulmonary exacerbation (0 [interquartile range, IQR: 0-2] vs. 0 [IQR: 0-7], p = 0.001), and more non-invasive ventilation support (2.6% vs. 0.9%, p = 0.008) than patients in group 1. Conclusion: The ineligible group had worse clinical outcomes than the eligible group. This highlights their need for life-changing drugs to improve clinical outcomes. | |
dc.identifier.e-issn | 1099-0496 | |
dc.identifier.issn | 8755-6863 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14701/43206 | |
dc.language.iso | English | |
dc.title | Comparison of clinical features of cystic fibrosis patients eligible but not on CFTR modulators to ineligible for CFTR modulators | |
dc.type | Article |